BIIB:NASDAQ
Biogen Inc
$215.50
arrow_upward
+2.26%(+4.77) 1D
Sep 10, 1:10:23 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$209.92
High
$216.30
Low
$208.93
Mkt. cap
31.84B
Avg. vol.
823.56K
Volume
370.84K
P/E ratio
38.16
52-wk high
$225.80
52-wk low
$135.39
EPS
$5.65
Beta
0.17
Shares outstanding
147.75M
No. of employees
8K
Open
$209.92
High
$216.30
Low
$208.93
Mkt. cap
31.84B
Avg. vol.
823.56K
Volume
370.84K
P/E ratio
38.16
52-wk high
$225.80
52-wk low
$135.39
EPS
$5.65
Beta
0.17
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
GuruFocus
·
1 hour ago
BIIB Maintained by HSBC -- Price Target Raised to $175
ad-hoc-news.de
·
3 hours ago
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures
Investing.com
·
4 hours ago
Stifel reiterates Biogen stock rating on immunology pipeline
Kalkine Media
·
20 hours ago
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises?
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com